Please note: The following announcement supersedes any information contained in this article. On March 30, 2007, Novartis, in compliance with an FDA request, suspended marketing and sales of its irritable bowel/constipation drug tegaserod maleate (Zelnorm) after an analysis of its clinical database pointed to a higher incidence of myocardial infarction, stroke, and unstable angina among patients taking the drug. For updated information on this issue, see the Medscape Alert Center on tegaserod.
In this second installment in our quarterly literature review series on topical issues in irritable bowel syndrome (IBS) and chronic constipation, 3 original research studies are reviewed. These reports describe new information regarding the pathophysiology of IBS, the role of alternative therapies in the treatment of IBS, and the treatment of constipation.